Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma

Cancer Science

Volumn 94, Issue 3, 2003, Pages 308-313

  Ito, Akira ^a   Tanaka, Kouji ^a   Kondo, Kazuyoshi ^a   Shinkai, Masashige ^a,c   Honda, Hiroyuki ^a   Matsumoto, Kazuhiko ^b   Saida, Toshiaki ^b   Kobayashi, Takeshi ^a  

^a NAGOYA UNIVERSITY   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LIPOSOME; MAGNETITE; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL STUDY; CONTROLLED STUDY; EXPERIMENTAL MELANOMA; HYPERTHERMIC THERAPY; HYSTERESIS; MAGNETIC FIELD; MELANOMA B16; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SURFACE CHARGE; TEMPERATURE; THERMOGENESIS; TIME; TREATMENT OUTCOME; TUMOR IMMUNITY; TUMOR REGRESSION;

ANIMALS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HSP70 HEAT-SHOCK PROTEINS; HYPERTHERMIA, INDUCED; IMMUNOTHERAPY; INTERLEUKIN-2; MAGNETICS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SURVIVAL; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0038636162     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01438.x     Document Type: Article

References (39)

1. Van der Zee J. Heating the patient: a promising approach? Annu Oncol 2002; 13: 1173-84.
2. Abe M, Hiraoka M, Takahashi M, Egawa S, Matsuda C, Onoyama Y, Morita K, Kakehi M, Sugahara T. Multi-institutional studies on hyperthermia using an 8-MHz radiofrequency capacitive heating device (Thermotron RF-8) in combination with radiation for cancer therapy. Cancer 1986; 58: 1589-95.
3. Jordan A, Wust P, Fahling H, John W, Hinz A, Felix R. Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int J Hyperthermia 1993; 9: 51-68.
4. Minamimura T, Sato H, Kasaoka S, Saito T, Ishizawa S, Takemori S, Tazawa K, Tsukada K. Tumor regression by inductive hyperthermia combined with hepatic embolization using dextran magnetite-incorporated microspheres in rats. Int J Oncol 2000; 16: 1153-8.
5. Shinkai M, Matsui M, Kobayashi T. Heat properties of magnetoliposomes for local hyperthermia. Jpn J Hyperthermic Oncol 1994; 10: 168-77.
6. Shinkai M, Yanase M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: in vitro study. Jpn J Cancer Res 1996; 87: 1179-83.
7. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: ex vivo study. Jpn J Cancer Res 1997; 88: 630-2.
8. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: an in vivo study. Jpn J Cancer Res 1998; 89: 463-9.
9. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Antitumor immunity induction by intracellular hyperthermia using magnetite cationic liposomes. Jpn J Cancer Res 1998; 89: 775-82.
10. Burdon RH, Slater A, McMahon M, Cato AC. Hyperthermia and the heat-shock proteins of HeLa cells. Br J Cancer 1982; 45: 953-63.
11. Sciandra JJ, Subjeck JR. Heat shock proteins and protection of proliferation and translation in mammalian cells. Cancer Res 1984; 44: 5188-94.
12. Srivastava PK, Ménoret A, Basu S, Binder R, Quade K. Heat shock proteins come of age: primitive functions acquired new roles in an adaptive world. Immunity 1998; 8: 657-65.
13. Ménoret A, Chandawarkar R. Heat-shock protein-based anticancer immunotherapy: an idea whose time has come. Semin Immunol 1998; 25: 654-60.
14. Castelli C, Ciupitu AM, Rini F, Rivoltini L, Mazzocchi A, Kiessling R, Parmiani G. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 2001; 61: 222-7.
15. Ito A, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer Immunol Immunother 2001; 50: 515-22.
16. Ito A, Shinkai M, Honda H, Yoshikawa K, Saga S, Wakabayashi T, Yoshida J, Kobayashi T. Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol Immunother 2003; 52: 80-8.
17. Farrar WL, Johnson HM, Farrar JJ. Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2. J Immunol 1981; 126: 1120-5.
18. Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984; 223: 1412-4.
19. Hadden JW. Recent advances in the preclinical and clinical immunopharmacology of interleukin-2: emphasis on IL-2 as an immunorestorative agent. Cancer Detect Prev 1988; 12: 537-52.
20. Gasson JC, Weisbart RH, Kaufman SE, Clark SC, Hewick RM, Wong GG, Golde DW. Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. Science 1984; 226: 1339-42.
21. Horiguchi J, Warren MK, Kufe D. Expression of the macrophage-specific colony-stimulating factor in human monocytes treated with granulocyte-macrophage colony-stimulating factor. Blood 1987; 69: 1259-61.
22. Burgess AW, Metcalf D. The nature and action of granulocyte-macrophage colony stimulating factors. Blood 1980; 56: 947-58.
23. Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Bast RC Jr, Gilbert CJ, Oette DH. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318: 869-76.
24. Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, Broxineyer HE, Henney C, Gutterman JU. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 1987; 317: 1545-52.
25. Groopman JE, Mitsuyasu RT, DeLeo MJ, Oette DH, Golde DW. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 1987; 317: 593-8.
26. Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitley M, Frei E 3rd, Schnipper LE. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988; 319: 593-8.
27. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-96.
28. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-43.
29. Owen CS, Sykes NL. Magnetic labeling and cell sorting. J Immunol Methods 1984; 73: 41-8.
30. Flotte TJ, Springer TA, Thorbecke GJ. Dendritic cell and macrophage staining by monoclonal antibodies in tissue sections and epidermal sheets. Am J Pathol 1983; 111: 112-24.
31. Suzuki M, Shinkai M, Honda H, Kobayashi T. Anti-cancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes. Melanoma Res 2003; in press.
32. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1998; 12: 991-1045.
33. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996; 8: 271-80.
34. Todryk S, Melcher AA, Hardwick N, Linardakis E, Bateman A, Colombo MP, Stoppacciaro A, Vile RG. Heat shock protein 70 induced during tumor cell killing induces Thl cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 1999; 163: 1398-408.
35. Speiser DE, Miranda R, Zakarian A, Bachmann MF, Mckall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM, Ohashi PS. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 1997; 186: 645-53.
36. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52-8.
37. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptide. Science 1995; 269: 1585-8.
38. Wells AD, Rai SK, Salvato MS, Band H, Malkovsky M. Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. Int Immunol 1998; 10: 609-17.
39. Shimizu K, Fields RC, Giedlin M, Mulé JJ. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci USA 1999; 96: 2268-73.